María Eva Mingot-Castellano

Dr. María Eva Mingot-Castellano

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Haematologica
Verified
Journal Article
Closed access
AHA. Huth-Kuhne
A. Huth-Kuhne
FBF. Baudo
F. Baudo
PCP. Collins
P. Collins
JIJ. Ingerslev
J. Ingerslev
CKC. M. Kessler
C. M. Kessler
JSJ. St-Louis
J. St-Louis
Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding and an isolated prolonged aPTT. AHA may, however, present without any bleeding symptoms, therefore an isolated prolonged aPTT should always be investigated further irrespective of the clinical findings. Control of acute bleeding is the first priority, and we recommend first-line therapy with bypassing agents such as recombinant activated FVII or activated prothrombin complex concentrate. Once the diagnosis has been achieved, immediate autoantibody eradication to reduce subsequent bleeding risk should be performed. We recommend initial treatment with corticosteroids or combination therapy with corticosteroids and cyclophosphamide and suggest second-line therapy with rituximab if first-line therapy fails or is contraindicated. In contrast to congenital hemophilia, no comparative studies exist to support treatment recommendations for patients with AHA, therefore treatment guidance must rely on the expertise and clinical experience of specialists in the field. The aim of this document is to provide a set of international practice guidelines based on our collective clinical experience in treating patients with AHA and contribute to improved care for this patient group.

7 June 2010 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
PCPeter Collins
Peter Collins
FBFrancesco Baudo
Francesco Baudo
AHAngela Huth-Kühne
Angela Huth-Kühne
JIJørgen Ingerslev
Jørgen Ingerslev
CKCraig M Kessler
Craig M Kessler
HLHervé Lévesque
Hervé Lévesque
Acquired hemophilia A (AHA) is a rare bleeding disorder caused by an autoantibody to coagulation factor (F) VIII. It is characterized by soft tissue bleeding in patients without a personal or family history of bleeding. Bleeding is variable, ranging from acute, life-threatening hemorrhage, with 9-22% mortality, to mild bleeding that requires no treatment. AHA usually presents to clinicians without prior experience of the disease, therefore diagnosis is frequently delayed and bleeds under treated.

17 November 2014 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
Tomás José González-LópezTomás José González-López
Tomás José González-López
CPCristina Pascual
Cristina Pascual
MÁMaría Teresa Álvarez‐Román
María Teresa Álvarez‐Román
FFFernando Fernández‐Fuertes
Fernando Fernández‐Fuertes
BSBlanca Sánchez‐González
Blanca Sánchez‐González
JGJosé Ramón González‐Porras
José Ramón González‐Porras
Eltrombopag is effective and safe in immune thrombocytopenia (ITP). Some patients may sustain their platelet response when treatment is withdrawn but the frequency of this phenomenon is unknown. We retrospectively evaluated 260 adult primary ITP patients (165 women and 95 men; median age, 62 years) treated with eltrombopag after a median time from diagnosis of 24 months. Among the 201 patients who achieved a complete remission (platelet count >100 × 109/l), eltrombopag was discontinued in 80 patients. Reasons for eltrombopag discontinuation were: persistent response despite a reduction in dose over time (n = 33), platelet count >400 × 109/l (n = 29), patient's request (n = 5), elevated aspartate aminotransferase (n = 3), diarrhea (n = 3), thrombosis (n = 3), and other reasons (n = 4). Of the 49 evaluable patients, 26 patients showed sustained response after discontinuing eltrombopag without additional ITP therapy, with a median follow‐up of 9 (range, 6–25) months. These patients were characterized by a median time since ITP diagnosis of 46.5 months, with 4/26 having ITP < 1 year. Eleven patients were male and their median age was 59 years. They received a median of 4 previous treatment lines and 42% were splenectomized. No predictive factors of sustained response after eltrombopag withdrawal were identified. Platelet response following eltrombopag cessation may be sustained in an important percentage of adult primary ITP patients who achieved CR with eltrombopag. However, reliable markers for predicting which patients will have this response are needed. Am. J. Hematol. 90:E40–E43, 2015.

20 August 2012 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
MMMaría Eva Mingot-Castellano
María Eva Mingot-Castellano
LTL Tengborn
L Tengborn
FBF Baudo
F Baudo
AHA Huth‐Kühne
A Huth‐Kühne
PKPaul N. Knoebl
Paul N. Knoebl
OCOn Behalf Of The Each2 Registry Contributors
On Behalf Of The Each2 Registry Contributors

16 December 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
BFBruno Fattizzo
Bruno Fattizzo
MMMarc Michel
Marc Michel
JGJuri Alessandro Giannotta
Juri Alessandro Giannotta
DHDennis Lund Hansen
Dennis Lund Hansen
MAMaria Arguello
Maria Arguello
WBWilma Barcellini
Wilma Barcellini
Evans syndrome (ES) is a rare condition, defined as the presence of 2 autoimmune cytopenias, most frequently autoimmune hemolytic anemia and immune thrombocytopenia (ITP) and rarely autoimmune neutropenia. ES can be classified as primary or secondary to various conditions, including lymphoproliferative disorders, other systemic autoimmune diseases, and primary immunodeficiencies, particularly in children. In adult ES, little is known about clinical features, disease associations, and outcomes. In this retrospective international study, we analyzed 116 adult patients followed at 13 European tertiary centers, focusing on treatment requirements, occurrence of complications, and death. ES was secondary to or associated with underlying conditions in 24 cases (21%), mainly other autoimmune diseases and hematologic neoplasms. Bleeding occurred in 42% of patients, mainly low grade and at ITP onset. Almost all patients received first-line treatment (steroids with or without intravenous immunoglobulin), and 23% needed early additional therapy for primary refractoriness. Additional therapy lines included rituximab, splenectomy, immunosuppressants, thrombopoietin receptor agonists, and others, with response rates >80%. However, a remarkable number of relapses occurred, requiring ≥3 therapy lines in 54% of cases. Infections and thrombotic complications occurred in 33% and 21% of patients, respectively, mainly grade ≥3, and correlated with the number of therapy lines. In addition to age, other factors negatively affecting survival were severe anemia at onset and occurrence of relapse, infection, and thrombosis. These data show that adult ES is often severe and marked by a relapsing clinical course and potentially fatal complications, pinpointing the need for high clinical awareness, prompt therapy, and anti-infectious/anti-thrombotic prophylaxis.

18 December 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JGJosé Ramón González‐Porras
José Ramón González‐Porras
MMMaría Eva Mingot-Castellano
María Eva Mingot-Castellano
MAMarcio M. Andrade
Marcio M. Andrade
RARafael Alonso
Rafael Alonso
ICIsabel Caparrós
Isabel Caparrós
Tomás José González-LópezTomás José González-López
Tomás José González-López